Utilization of commercially available rapid platforms for microbial identification from positive blood cultures is useful during periods of, or in laboratories with, limited expert staffing. We compared the results of the FilmArray Standard-of-care testing identified organisms in 20 positive blood cultures, which were not represented on the BCID Panel. Seven (3.5 %) blood cultures demonstrated a discrepancy between the methods, which could not be attributed to either a lack of representation on the panel or unclear separate detection of organisms in a mixed blood culture of a shared genus or grouping of organisms, e.g. Staphylococcus or Enterobacteriaceae. One (0.5 %) blood culture yielded invalid results on two separate panels, so it was eliminated from the study. The easy-to-use FilmArray ® technology shows good correlation with blood culture identification and antibiotic resistance detection performed by conventional methods. This technology may be particularly useful in laboratories with limited staffing or limited technical expertise.
INTRODUCTION
Bloodstream infections remain a leading cause of morbidity and mortality in hospitalized patients. As such, clinical microbiology laboratories continuously seek technologies that provide rapid identification and antimicrobial susceptibility information about micro-organisms isolated from blood cultures. Several platforms are available that provide a range of result options, including single-analyte tests and multiplex panels (Altun et al., 2013; Blaschke et al., 2012; Buchan et al., 2013; Croxatto et al., 2012; Oliviera et al., 2002; Paolucci et al., 2010; Wolk et al., 2009) . The bases for these systems include fluorescent peptide-nucleic acid probes, nanoparticle-laden oligonucleotide or antibody probes, ferrocenelabelled oligonucleotide probes, real-time nucleic acid amplification, and matrix-assisted laser desorption ionization timeof-flight MS (MALDI-TOF MS). In addition to shortened turnaround times, attractive features of these technologies include cost-effectiveness, provision of highly accurate and reproducible results, user-friendliness and detection of a broad range of microbial pathogens as well as antimicrobial drug-resistance targets (Kothari et al., 2014) . All of the emergent technologies offer some of these attributes, but no single system is able to satisfy all of these criteria. Given the number, diversity and cost-range of the currently available systems, clinical microbiologists are faced with many challenges when selecting the appropriate system or systems to best accommodate their needs.
Another consideration often included in the decisionmaking process for purchasing new test systems is the availability of properly trained laboratory personnel to perform the tests on all shifts during which the technology is to be used. Ideally, for identification of bloodstream pathogens, such technologies would be used whenever positive blood cultures are detected, which could occur, at any time, during all shifts. Most clinical microbiology laboratories do not operate with a full complement of diversely skilled medical laboratory technologists around the clock. Often, the largest and most specialized cadre of technologists work during normal business hours, and a smaller and more generalized group of technologists staff the laboratory during the remaining shifts. Similarly, many small hospital laboratories employ generalist technologists who have duties in other laboratory areas, including clinical chemistry, haematology and the blood bank, in addition to microbiology. It is sometimes difficult to maintain adequate competency in a single area in such situations when so many areas of the clinical laboratory require the technologist's attention. For this reason alone, it is important to utilize technology for identification of blood culture isolates that is rapid, is accurate and requires minimal advanced training.
The BioFire ® FilmArray ® (BioFire Diagnostics) line of US Food and Drug Administration (FDA)-cleared, nucleic acid amplification and detection assays are some of the first multiplex platforms available for the detection of infectious agents directly from clinical specimens (Altun et al., 2013; Blaschke et al., 2012) . These assays combine all steps, including nucleic acid extraction, purification, amplification and detection, into a single, closed-system plastic-film pouch. Following rehydration of pouch reagents and injection of the clinical sample, the FilmArray ® pouch is loaded into the FilmArray ® instrument. The instrument performs liquid handling, temperature cycling, amplicon detection and high-resolution melting analysis steps without user intervention. Hands-on time required for pre-analytical manipulations is less than 2 min, and the instrument generates results in approximately 1 h. The FilmArray ® Blood Culture Identification (BCID) panel is an FDA-cleared in vitro diagnostic product that permits detection of 27 microbial targets, including 24 genus-and species-specific targets for Gram-positive and Gram-negative bacteria and fungi, as well as mecA, vanA/B and bla KPC . If a common member of the genera Staphylococcus or Streptococcus, or of the family Enterobacteriaceae, is detected, this generic or family name, respectively, is listed on the FilmArray ® BCID report, followed by the specific names, if the organisms are represented on the panel.
For this study, we compared the FilmArray ® BCID panel and conventional standard-of-care methods for microorganism identification and antibiotic resistance gene detection from positive blood cultures. Because utilization of commercially available rapid platforms for microbial identification from positive blood cultures is useful during periods of, or in laboratories with, limited expert staffing, we simulated these scenarios by utilizing technologists who were not trained in either molecular biology or routine bacteriology methods. BCID analysis was performed according to the manufacturer's instructions. In brief, prior to sample addition, the reagent compartments of a FilmArray ® BCID pouch were rehydrated using the manufacturersupplied rehydration solution. Next, a 100 µl aliquot of a positive blood culture broth was mixed with an aliquot of sample buffer. Subsequently, this mixture was injected into the BCID pouch and then loaded into the FilmArray ® instrument. All reaction and data analysis steps were completed approximately 60 min after pouch loading.
To evaluate the user-friendliness of the FilmArray ® system, and to simulate operation of the system by personnel not specifically trained in molecular biology or bacteriology methods, medical laboratory scientists unfamiliar with either discipline performed all BCID analyses. Six medical laboratory scientists performed the BCID testing and, after which, commented on non-analytical parameters, such as technical expertise required for performing the FilmArray ® testing and estimation of easeof-use of the product. If invalid results were obtained for a specimen, a second BCID pouch was run on the specimen. If the second run was also invalid, the result was recorded as 'invalid'.
BCID testing of positive blood cultures was considered consistent with standard-of-care testing if the organism identified by BCID was the most specific identification possible according to the panel (Table 1) . For example, if Enterococcus faecalis and coagulase-negative Staphylococcus (CoNS) were identified by standard-of-care methods, and BCID detected Enterococcus and Staphylococcus, respectively, the two cultures would be considered consistent. In cases of mixed cultures of a shared genus or grouping of organisms, BCID and standard-of-care testing were considered consistent if BCID detected at least the generic name of the organism for which a specific name was not included on the panel. For example, in the event of a mixed culture of CoNS and Staphylococcus aureus, the BCID panel reports 'Staphylococcus' and also 'Staphylococcus aureus'. As both taxonomic descriptors are also given when just S. aureus alone is detected, it is not possible to discern whether CoNS was detected in addition to S. aureus.
Standard-of-care testing. Aliquots of broths from positive aerobic and paediatric blood culture bottles were Gram stained and inoculated onto 5 % sheep's blood agar, chocolate agar, Columbia CNA agar and MacConkey agar. For lytic and resin-containing anaerobic media, CDC anaerobic blood agar was added to the battery of subculture media. Subcultures were incubated in an atmosphere enriched with 5 % CO 2 at 35 C for a minimum of 18 h. Anaerobic blood agar plates were incubated in an anaerobic atmosphere for a minimum of 48 h before culture examination.
Following incubation of the subculture media, each colony morphotype was identified by either the VITEK ® 2 or MALDI-TOF MS (Bruker BiotyperÔ; Bruker Daltonics). Detection of antimicrobial resistance mechanisms was achieved using phenotypic methods, including oxacillin MIC determination and cefoxitin disc testing to identify methicillin-resistant Staphylococcus aureus (MRSA), vancomycin MIC determination for identification of vancomycin-resistant Enterococcus (VRE), and MIC and modified Hodge test-based identification of carbapenem-resistant Enterobacteriaceae. Discrepancies between BCID and standard-of-care testing methods were resolved by sequencing of the rpoB gene performed at an outside laboratory.
Statistical analysis. The efficient-score method was used to calculate the 95 % confidence interval for all sensitivities and specificities presented.
RESULTS
According to the standard-of-care testing methods, of the 200 blood cultures analysed in this study, 181 (90.5 %) contained only a single organism and the remaining 19 (9.5 %) contained up to three organisms. The most frequently identified organisms by BCID, and confirmed by standard-of-care testing, were Staphylococcus spp. (46), Staphylococcus aureus (32), Klebsiella pneumoniae (23), Escherichia coli (23) and Enterococcus (21). Table 1 lists the organisms identified in the aforementioned 200 cultures, their frequency, and any phenotypic Candida spp. were recovered from seven (3.5 %) of 200 blood cultures by standard-of-care testing, with BCID correctly identifying each species represented on the panel: C. albicans (n=5), C. glabrata (n=1) and C. parapsilosis (n=1).
In one of these seven cultures, standard-of-care identified C. albicans in addition to C. lusitaniae in mixed culture. Although C. albicans was detected by BCID testing, as previously mentioned, C. lusitaniae is not represented on the BCID panel and was therefore not identified.
Of 19 mixed cultures, provided the organism was represented, the BCID panel correctly identified all organisms detected by standard-of-care methods. Seven instances of mixed blood cultures with up to three organisms had complete agreement between standard-of-care testing and the most specific identification possible by BCID testing. There were 11 instances of mixed blood cultures with organisms identified by standard-of-care but not by the BCID due to lack of representation on the panel or a second member of an organism genus or grouping, e.g. Staphylococcus or Enterobacteriaceae, without more specific representation on the panel. In one mixed blood culture, the BCID panel identified an Enterococcus sp., a Streptococcus sp. and a Staphylococcus sp.; however, standard-of-care testing detected only the Enterococcus sp. and a CoNS.
Seven (3.5 %) blood cultures demonstrated a discrepancy between the standard-of-care identification and the BCID identification that could not be attributed to either a lack of representation on the panel or unclear separate detection of organisms in a mixed blood culture of a shared genus or group, e.g. Staphylococcus or Enterobacteriaceae. These positive blood cultures and their identifications by standardof-care and BCID are displayed in Table 2 . In addition, a single positive blood culture of Escherichia coli identified by standard-of-care resulted in two separate invalid reactions when tested by BCID.
Overall, compared with standard-of-care methods, FilmArray ® BCID detected every organism represented on the panel with a sensitivity of 100 % and a specificity of 98 %. The single invalid BCID test was excluded from these analyses.
DISCUSSION
Methods that can detect nucleic acids in clinical specimens have become important tools for the diagnosis of infectious diseases. The ability to rapidly and accurately identify pathogenic micro-organisms and genes encoding antimicrobial resistance mechanisms can often provide clinically useful information that can help guide both antimicrobial chemotherapy and infection control practices (Barenfanger et al., 2008; Beekmann et al., 2003; Doern et al., 1994) . However, there is a paucity of easy-to-use, rapid and highly accurate direct-detection systems currently available. Even more unique is the ability to perform these rapid analyses without Gram stain interpretation. Most current commercial rapid microbial identification systems for use with positive blood cultures require an initial Gram stain result to select the most appropriate assay or panel to use before proceeding with testing. The BCID panel contains the most commonly encountered Gram-positive and Gram-negative bacteria as well as yeast on a single panel. This allows for technologists unfamiliar with Gram stain performance and interpretation to perform the FilmArray ® assay. Additionally, mixed Gram-positive and Gram-negative or yeast infections may be detected using a single test. In this evaluation, the FilmArray ® BCID panel was compared to standard-of-care testing within a large-volume clinical microbiology laboratory. To simulate a laboratory setting staffed by personnel without molecular biology or bacteriology training, such as that typical of regional laboratories relying on generalist medical laboratory personnel, or during non-peak hours in larger consolidated laboratories, BCID panel testing was performed by medical laboratory technologists who were not trained in either molecular biology or routine bacteriology methods. Additionally, BCID testing was performed without the knowledge of Gram stain results obtained by standard-of-care testing.
Results from these analyses were very sensitive and accurate, with a sensitivity and specificity for each panel organism identified at 100 % and 98 %, respectively. In 86 % of the samples, BCID testing successfully detected the organism(s) that were ultimately identified by standard-ofcare methods. Other than the seven inconsistent cultures, the remaining 20 were ultimately identified as organisms that are not represented on the BCID panel. Instances of these organisms in pure culture would probably be easily resolved, as a negative result by BCID would prompt the technologist to search the Gram stain and subcultures for organisms not represented on the BCID panel (e.g. anaerobes or other infrequently encountered organisms). If the clinical laboratory were performing the BCID assay without the benefit of the Gram stain, as was the case in this study, it is possible a negative BCID result could prompt the technologist either to repeat the assay or presume the culture was falsely flagged positive by the automated culture instrument. Depending on how the technologist handled the scenario, this could result in wasting consumable resources and technologist time or, worse, missing reporting of a critical laboratory value. Mixed cultures, discussed below, would also pose additional unique problems in interpretation of BCID results independent of the Gram stain. Therefore, although the BCID assay could certainly be run prior to the interpretation of the Gram stain, in this scenario it would be prudent to interpret the results as preliminary information to be confirmed when Gram stain interpretation is available.
Antimicrobial resistance genes for methicillin (mecA) and vancomycin (van A/B) were detected in all isolates found to be MRSA (n=10) or VRE (n=7) by phenotypic testing. The rapid detection, or lack thereof, of genes responsible for antimicrobial resistance allows for earlier actionable results important for antibiotic therapy. For example, a positive blood culture initial report of 'Enterococcus vanA/B detected' rather than a report of 'Gram-positive cocci in pairs and chains' has a great deal of added clinical value. Within approximately 1 h from the blood culture flagging positive, the former information can be reported to a physician, who can then transition to more directed therapy. In our laboratory, standard culture and phenotypic methods for finalized identification and susceptibility testing required, on average, 47 h (data not shown) to generate a report of VRE or MRSA. In the interim, the patient is left on empiric treatment, which may be more costly or less effective than more directed therapy.
The reporting of rapid molecular identification, such as that by FilmArray ® BCID, poses an inherent risk for misinterpretation by the unseasoned or misinformed clinician. Care must be taken when building the language used in reporting these results to clinicians. For instance, a finding of Staphylococcus sp. with mecA detected could result in a situation of too aggressive treatment if the clinician is unaware that many CoNS carry the mecA gene and this result does not infer that MRSA is present. Appropriate planning with key stakeholders in the laboratory, information technology, infectious disease and other clinical services would be necessary to ensure proper education regarding the limitations of the technology and correct reporting and interpretation of the results.
Mixed blood cultures have the potential to cause additional confusion in the laboratory. Eleven mixed blood cultures had incomplete BCID identifications due either to the lack of representation of the organism on the BCID panel or to the presence of two members of the same genus or group. In the context of a mixed culture, positive results obtained from BCID testing resulting in clinical action, such as initiation of more focused antimicrobial therapy, may potentially result in inadequate treatment if a second, non-detected, organism is present. Additional organisms can, however, be suggested by Gram stain, perhaps performed on the main shift and definitively identified after subculture. The clinical significance of a premature narrowing of antimicrobial therapy would depend largely on the organisms involved. For example, if a second CoNS, or a CoNS identified after an initial S. aureus result, was noted on the standard-of-care work-up, it is unlikely to have any appreciable clinical significance. However, it is conceivable that an undetected second member of the Enterobacteriaceae could have significant clinical implications.
The seven positive blood cultures with discrepancies, not attributable to any reason previously discussed, consisted of both mixed and pure cultures. Klebsiella pneumoniae was detected by BCID in a culture from which MALDI-TOF MS identified Raoultella ornithinolytica, confirmed by rpoB gene sequencing. This is of interest as the 510(k) submission for BCID indicated R. ornithinolytica had been misidentified as K. oxytoca during premarket testing [BioFire Diagnostics, 510(k) ]. In another culture, Streptococcus spp. were detected by BCID while a similar organism, Granulicatella adiacens, was detected by standard-of-care testing. Three positive blood cultures in which Enterococcus was detected by BCID were not confirmed by standard-of-care testing. In one of these, a swarming Proteus mirabilis was also identified, but no Enterococcus sp. growth was noted on CNA agar, which is selective for Gram-positive organisms. It is also possible these three unconfirmed Enterococcus BCID results could have been due to the inherent increased sensitivity of molecular amplification, permitting detection of non-viable bacteria in the cultures, or DNA contamination of the culture system. In one culture the BCID was negative, but standard-of-care methods identified Staphylococcus pettenkoferi. Although a member of the genus Staphylococcus, as previously reported, S. pettenkoferi consistently failed detection by BCID testing [BioFire Diagnostics 510(k) ].
Although the FilmArray BCID assay is only FDA cleared for use with the BD BACTECÔ Plus Aerobic/F blood culture bottle, for this study we elected to use all blood culture bottles currently in use in our clinical laboratory. Pre-market studies were conducted evaluating the potential for interfering substances in 14 commonly used blood culture bottles produced from three different manufacturers. These studies included detection of panel-represented organisms, in addition to negative controls, from spiked simulated blood cultures. There was no demonstration of false-negative BCID results due to interference with the various bottle formulations. However, there were false positives reported from samples obtained from BacT/ALERT FAN bottles. An investigation concluded these false positives were due to a high bio-burden associated with the charcoal included in the media formulation. For this reason it is recommended that blood culture bottles containing formulations that include charcoal should not be used with the FilmArray BCID system. Other than the BD BACTECÔ Plus Aerobic/F culture bottle, the remaining three bottles used in this study were included as part of the list of 14 evaluated during pre-market testing, which found no evidence of interfering substances [BioFire Diagnostics 510(k)]. The potential for false-positive results would remain a concern regardless of the culture bottle used in cases of lot contamination with residual microbial nucleic acid. The interpretation of BCID results along with other laboratory data, such as the Gram stain and subculture, would be important in mitigating this potential risk.
The evaluation from the medical technologists, neither trained in molecular biology nor in routine bacteriology methods, noted that the BCID assay was extremely easy and simple to perform. As previously noted, these technologists received very brief training on the technology and procedure, much less than would be considered adequate by today's regulatory training standards for moderate-or highcomplexity clinical laboratory testing. It was noted that the result read-out was simple and concise, allowing for easy interpretation. The biohazardous waste generated by the BCID test was also minimal, as was the exposure to potentially infectious material. Lastly, including hands-on time, results were obtained within approximately 1 h and 15 min.
At the time of this study, our laboratory was able to provide definitive identification of all Gram-negative isolates in this study using MALDI-TOF MS on average 27 h from the time the bottle flagged positive. Availability of both definitive identification and susceptibility testing for all isolates took on average 47 h to fully complete from the time the blood culture bottle flagged positive.
While, in this study, we relied on the use of standard incubation time to grow isolates for MALDI-TOF MS analysis, it is important to note that institutions have also begun employing more rapid MALDI-TOF MS-based methods including short-term subculture incubation (Idelevich et al., 2014; Verroken et al., 2015) and the use of directfrom-broth methods (Lagac e-Wiens et al., 2012), which have shown promise in their ability to provide identifications directly from positive blood culture bottles within hours for laboratories that have MALDI-TOF MS capability. As noted above, however, MALDI-TOF MS currently lacks the ability to provide susceptibility data while molecular testing panels, such as the BCID, typically include the ability to detect the most common antimicrobial resistance markers.
Importantly, the implementation of rapid diagnostic methods requires clinicians and other healthcare practicioners to quickly act upon the result. Several studies (e.g. Perez et al., 2013; Southern et al., 2015) have shown that robust antimicrobial stewardship programmes are required for effective implementation of rapid diagostic methodologies.
Overall, the system performed very well compared with standard-of-care methods. In addition, the laboratory staff who performed the BCID testing reported that the platform is very user-friendly. Contributing to this ease-of-use, Gram stain interpretations are not required to perform the BCID test, allowing for technologists unfamiliar with routine bacteriology to perform the FilmArray ® assay. Many laboratories are staffed by generalist technologists with a wide range of microbiological technical expertise. Those platforms that are dependent on Gram stain results to guide panel choice are vulnerable to misclassification of Gram stain results by less experienced technologists. The FilmArray ® system overcomes this obstacle by obviating the dependency on Gram stain result by combining Gram-positive and Gram-negative bacteria and the five most clinically relevant Candida species in one panel. This technology will probably prove useful for correctly identifying pathogens and antimicrobial resistance markers in laboratories with limited staffing or in those laboratories staffed by personnel with limited technical expertise.
